World High Life PLC - Love Hemp appoints Chief Scientific Advisor London Stock Exchange
RNS Number : 3235P
World High Life PLC
09 June 2020

9 June 2020



World High Life PLC

 ("World High Life" or the "Company")

Love Hemp appoints Dr. Sepe Sehati

as Chief Scientific & Regulatory Advisor


World High Life Plc (AQSE: LIFE) (OTCQB: WRHLF) is pleased to announce that its wholly owned subsidiary, London-based CBD brand, Love Hemp Limited ("Love Hemp") , has appointed Dr. Sepe Sehati as Chief Scientific & Regulatory Advisor. Dr. Sehati is a healthcare innovator and a Fellow of the Royal Society of Medicine. A passionate advocate and practitioner of both critical thinking and tactical cross-pollination of disciplines, Sepe holds a Doctorate in Bioengineering from the University of Oxford.

Sepe's innovative approach to problem solving, fuelled through the application of diverse scientific fields, analytics, neuroscience, behavioural science and evidence-based principles, has led him to contribute to various high-profile initiatives ranging from President Obama's Transition Health Policy, to the UK Prime Minister's sustainable development plan, to the late Dr Richard Rockefeller's innovative healthcare models. Sepe is also an advisor for the UK's Centre for Medicinal Cannabis.

Highlights of Dr. Sehati's Appointment as Love Hemp's Chief Scientific & Regulatory Advisor

·    Dr. Sehati holds a Doctorate in Bioengineering from the University of Oxford

·    Fellow of the Royal Society of Medicine

·    Contributor to President Obama's Transition Health Policy

·    Contributor to the UK Prime Minister's sustainable development plan

·    Advisor for the Centre for Medicinal Cannabis

Tony Calamita, CEO at Love Hemp says: "We are proud to welcome Sepe to the Love Hemp team. His experience will be a tremendous asset as CBD continues to gain momentum with consumers. He will be instrumental as we expand our range of trusted CBD products."

Love Hemp's Chief Scientific & Regulatory Advisor Dr. Sepe Sehati added: "Having carried out a critical review of CBD in 2018, the WHO concluded that CBD is generally well tolerated with a good safety profile. As research surrounding suggested benefits for CBD use evolves, the evolution we are seeing around CBD product development reflects a shift in consumer demand, and it is more important than ever to ensure accessibility to trusted, regulated and high-quality CBD products. I am excited to be working with Love Hemp to ensure the brand continues on its path of being a standard-bearer for the CBD industry and for the development of a safe, legally compliant and thriving CBD industry in the UK."


For further information please contact:

David Stadnyk

Founder & CEO

World High Life PLC

North America toll-free, 1 (888) 616-WRHLF (9745)

+44 (0) 7926 397 675





AQSE Corporate Adviser

Mark Anwyl/Allie Feuerlein

Peterhouse Capital Limited

+44 (0) 20 7469 0930

Financial PR

Camilla Horsfall/Megan Ray


+44 (0) 20 7138 3224



For more information on World High Life please visit:

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.


Cautionary Note Regarding Forward Looking Information

We seek safe harbour. Some statements contained in this news release are "forward looking information" within the meaning of securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes" or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual results to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management's current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. We do not undertake to update any estimate at any particular time or in response to any particular event, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit